A voluntary preventative product recall of Cilest® 250/35 Oral Contraceptive Tablets (250μg norgestimate 35μg ethinyl estradiol) is being initiated by Janssen-Cilag International N.V.
The recall is due to a reported slower than expected solubility of an active ingredient whcih can potentially lead to decreased contraceptive effect.
It has been reported that the likelihood of patients experiencing an adverse event due to this appears to be very low.
Stock of Cilest® will be withdrawn from pharmacies.
Patients are requested to contact their doctor to be advised regarding the continuation of their treatment.
More information can be obtained on 2343 9000.
↧